Hearscape
← Therapeutics
Details checkedStrong evidenceCheckedtrial

SENS-501 by Sensorion

Also known as: OTOF-GT, SENS-501, Audiogene

Sensorion

Primary source
Company
Sensorion
Program Type
Therapeutic
Modality
Gene Therapy
Stage
Phase 1/2
Status
Active
Target Gene
OTOF
Route / Mode
Intracochlear injection
Confidence
94%
Status Confidence
Status confirmed
Evidence Strength
Strong evidence
Last Reviewed
2026-05-31
Geography
France, United Kingdom, Europe
Population
pediatric, congenital, genetic, otof-dfnb9, pre-lingual, bilateral, profound
Trial IDs
1
Mechanism

Dual-AAV intracochlear gene therapy delivers otoferlin to restore hearing in OTOF deficiency.

Indications
Hearing LossSensorineural Hearing LossGenetic Hearing LossOTOF-Related Hearing LossAuditory Neuropathy
Notes

Major OTOF competitor to Regeneron and Lilly; Sensorion continues to present Audiogene follow-up while advancing its broader hereditary-hearing-loss gene therapy franchise.

Evidence & Sources
3 structured sources
clinicaltrials
Supports: canonicalName, aliases, trialIds, stage, route, populationTags, geography
IDs: NCT06370351
Open
company
Supports: company, allCompanies, mechanism, targetGene, indications
IDs: SENS-501, OTOF-GT
Open
company
Supports: status, stage, notes
IDs: SENS-501
Open
Key Events
2024-04-15
ClinicalTrials.gov entry posted for Phase 1/2 SENS-501 study in children with OTOF-related hearing loss
2026-03-23
Sensorion reported six-month Audiogene update
Clinical Trials (1)
NCT06370351
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2
AC102 by AudioCure Pharma
Company: AudioCure Pharma · Small Molecule · Phase 2